Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

1.

[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.

Zanzonico P, Koehne G, Gallardo HF, Doubrovin M, Doubrovina E, Finn R, Blasberg RG, Riviere I, O'Reilly RJ, Sadelain M, Larson SM.

Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):988-97. Epub 2006 Apr 11.

PMID:
16607546
[PubMed - indexed for MEDLINE]
3.

Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Niller HH, Wolf H, Minarovits J.

Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Review.

PMID:
18432410
[PubMed - indexed for MEDLINE]
4.

Immunogenetic therapy for B-cell malignancies.

Kipps TJ, Chu P, Wierda WG.

Semin Oncol. 2000 Dec;27(6 Suppl 12):104-9. Review.

PMID:
11225994
[PubMed - indexed for MEDLINE]
5.

Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.

Delecluse HJ, Feederle R, Behrends U, Mautner J.

Semin Cancer Biol. 2008 Dec;18(6):409-15. doi: 10.1016/j.semcancer.2008.09.001. Epub 2008 Sep 30. Review.

PMID:
18938248
[PubMed - indexed for MEDLINE]
6.

Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones.

Jensen MC.

Cytotherapy. 2002;4(5):443-4. Review. No abstract available.

PMID:
12473219
[PubMed - indexed for MEDLINE]
7.

Genetically engineered T-cells for adoptive immunotherapy.

Pule M, Bollard CM, Heslop HE.

Curr Opin Mol Ther. 2002 Oct;4(5):467-75. Review.

PMID:
12435048
[PubMed - indexed for MEDLINE]
8.

Cellular immunotherapy in haematological malignancies.

Reid CD.

Br J Haematol. 1999 Apr;105 Suppl 1:7-10. Review. No abstract available.

PMID:
10330926
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk